title: Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease.
abstract: BACKGROUND
  Nesfatin-1, recently identified as a satiety regulator, elicits an anti-atherosclerosis effect. Our study was designed to determine whether there is an association between serum nesfatin-1 and the development and severity of peripheral arterial disease (PAD) in patients with type 2 diabetes mellitus (T2DM).
  
  
  METHODS
  This cross-sectional study included 355 T2DM patients (200 without PAD and 155 with PAD).
  
  
  RESULTS
  T2DM patients with PAD exhibited marked lower serum nesfatin-1 concentrations than those without PAD. Multivariable logistic regression analysis indicated an inverse association of serum nesfatin-1 concentrations with the development of PAD in T2DM patients (OR 0.008, 95% CI 0.002 to 0.028; P<0.001). Simple linear regression analysis showed a marked correlation between serum nesfatin-1 concentrations and body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), C-reactive protein (CRP), and ankle-brachial index (ABI) in T2DM patients. By contrast, multivariable analysis showed only BMI and ABI as independent correlates of serum nesfatin-1.
  
  
  CONCLUSIONS
  Our study shows an association of serum nesfatin-1 concentrations and the development and severity of PAD in T2DM patients.
authors.affiliation: Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Shimei
authors.initials: S
authors.lastname: Ding
authors.affiliation: Department of Nuclear Medicine, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Wei
authors.initials: W
authors.lastname: Qu
authors.affiliation: Department of Infectious Diseases, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Shuangsuo
authors.initials: S
authors.lastname: Dang
authors.affiliation: Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Xuan
authors.initials: X
authors.lastname: Xie
authors.affiliation: Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Jing
authors.initials: J
authors.lastname: Xu
authors.affiliation: Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Yuhuan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Aiyu
authors.initials: A
authors.lastname: Jing
authors.affiliation: Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Chunhong
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Junhong
authors.initials: J
authors.lastname: Wang
mesh_terms: D002135:Calcium-Binding Proteins / Q000097:blood*; D004268:DNA-Binding Proteins / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000097:blood*; D000080866:Nucleobindins; D058729:Peripheral Arterial Disease / Q000097:blood* / Q000150:complications*
chemical_list: D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins
references.citation: Med Sci Monit. 2012 Mar;18(3):CR131-4
references.pmid: 22367123
references.citation: Curr Treat Options Cardiovasc Med. 2007 Apr;9(2):159-70
references.pmid: 17484818
references.citation: Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1642-7
references.pmid: 20335376
references.citation: Peptides. 2013 Aug;46:167-71
references.pmid: 23806888
references.citation: Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6
references.pmid: 19474390
references.citation: Chin Med J (Engl). 2011 Dec;124(24):4264-8
references.pmid: 22340397
references.citation: Clin Exp Hypertens. 2015;37(1):51-6
references.pmid: 24678977
references.citation: Nature. 2006 Oct 12;443(7112):709-12
references.pmid: 17036007
references.citation: Am J Med. 2004 Feb 15;116(4):236-40
references.pmid: 14969651
references.citation: J Am Coll Cardiol. 2004 Dec 21;44(12):2293-300
references.pmid: 15607389
references.citation: J Vasc Surg. 2005 Apr;41(4):625-30
references.pmid: 15874926
references.citation: Cardiovasc Hematol Agents Med Chem. 2013 Mar;11(1):3-8
references.pmid: 22845899
references.citation: Clin Endocrinol (Oxf). 2010 Oct;73(4):484-90
references.pmid: 20550530
references.citation: Peptides. 2012 Jul;36(1):39-45
references.pmid: 22561242
references.citation: Endocrine. 2012 Dec;42(3):694-9
references.pmid: 22367584
references.citation: J Clin Hypertens (Greenwich). 2012 Mar;14(3):144-8
references.pmid: 22372773
references.citation: Diabetes Care. 2012 Jan;35 Suppl 1:S64-71
references.pmid: 22187472
references.citation: BMC Fam Pract. 2011;12:96
references.pmid: 21929797
references.citation: Lancet. 2001 Oct 13;358(9289):1257-64
references.pmid: 11675083
references.citation: Cardiol Rev. 2014 May-Jun;22(3):147-51
references.pmid: 24618929
references.citation: Vasa. 2013 Sep;42(5):331-9
references.pmid: 23989068
references.citation: Curr Opin Lipidol. 2013 Oct;24(5):410-8
references.pmid: 24005217